Medicina, Vol. 57 No. 1, 2021.
Pregledni rad
https://doi.org/10.21860/medflum2021_365335
Axillary surgery for invasive breast cancer treatment; evolution, current guidelines and controversis
Ana Car Peterko
; KBC Rijeka, Rijeka, Hrvatska
Sažetak
There has been a constant trend of de-escalation in axillary surgery for invasive breast cancer treatment in the last few decades. From the beginning of this century sentinel lymph node biopsy is a gold standard for the axillary staging of early breast cancer patients. Ongoing trials are aiming to determine if any type of axillary surgery is justified for the breast cancer treatment of the above-mentioned population. At the same time,the indications for preoperative systemic oncology treatment are expanding. However, for the axillary surgery following neoadjuvant treatment, very conservative approach remained the standard treatment until 2017, with the axillary lymph dissection as the only valid option. Although sentinel node biopsy after preoperative systemic treatment is recommended option by all relevant breast cancer treatment guidelines, a tremendous resistance is present in adopting this concept into everyday clinical practice. This review is a demonstration of the scientifically based evolution of the current guidelines in axillary surgery, the existing controversies, and the ongoing trials that are aiming to resolve them.
Ključne riječi
axilla; breast cancer; lymph node dissection; neoadjuvant therapy; sentinel
Hrčak ID:
251270
URI
Datum izdavanja:
1.3.2021.
Posjeta: 2.074 *